113 related articles for article (PubMed ID: 31307200)
21. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
22. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
23. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
24. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis.
Liu W; Yang J; Chi PD; Zheng X; Dai SQ; Chen H; Xu BL; Liu WL
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1346-53. PubMed ID: 24025389
[TBL] [Abstract][Full Text] [Related]
26. Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer.
Lamy PJ; Plassot C; Pujol JL
PLoS One; 2015; 10(6):e0128836. PubMed ID: 26030627
[TBL] [Abstract][Full Text] [Related]
27. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer.
Mena E; Camacho V; Estorch M; Fuertes J; Flotats A; Carrió I
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1399-404. PubMed ID: 15221296
[TBL] [Abstract][Full Text] [Related]
28. [Feasibility and clinical value of whole body diffusion weighted magnetic resonance imaging in detection of bone metastases].
Li S; Xue HD; Sun F; Jin ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):192-9. PubMed ID: 19507599
[TBL] [Abstract][Full Text] [Related]
29. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Cheran SK; Herndon JE; Patz EF
Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
[TBL] [Abstract][Full Text] [Related]
30. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
31. Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy.
Yang S; Dong Q; Yao M; Shi M; Ye J; Zhao L; Su J; Gu W; Xie W; Wang K; Du Y; Li Y; Huang Y
Nucl Med Biol; 2009 Apr; 36(3):313-21. PubMed ID: 19324277
[TBL] [Abstract][Full Text] [Related]
32. Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: comparison with 99MTc-methylene diphosphonate scintigraphy.
Frat A; Ağildere M; Gençoğlu A; Cakir B; Akin O; Akcali Z; Aktaş A
J Comput Assist Tomogr; 2006; 30(1):151-6. PubMed ID: 16365592
[TBL] [Abstract][Full Text] [Related]
33. Human epididymis protein 4 in endometrial cancer: A meta-analysis.
Li LM; Zhu YX; Zhong Y; Su T; Fan XM; Xi Q; Li MY; Fu J; Tan H; Liu S
Clin Chim Acta; 2018 Jul; 482():215-223. PubMed ID: 29630870
[TBL] [Abstract][Full Text] [Related]
34. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
[TBL] [Abstract][Full Text] [Related]
35. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients.
Rodrigues M; Stark H; Rendl G; Rettenbacher L; Datz L; Studnicka M; Pirich C
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):62-8. PubMed ID: 26844431
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
[TBL] [Abstract][Full Text] [Related]
38. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
39. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
40. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
